0001564590-20-051311 | 10-Q | XBRL Viewer

Leases - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
Oct. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Monthly rental payments	$ 4,000
Operating lease expense		$ 0	$ 262,000	$ 0	$ 524,000
Rent expense		13,000	0	25,000	0
Variable lease expense		0	130,000	0	237,000
Short term lease cost		$ 0	$ 22,000	$ 0	$ 37,000

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Mar. 31, 2020
Current Assets
Cash and cash equivalents	$ 17,656	$ 27,356
Accounts receivable	19	111
Prepaid expenses and other current assets	1,810	851
Total current assets	19,485	28,318
Fixed assets, net	22	0
Prepaid expenses and other assets, net	1,137	123
Total assets	20,644	28,441
Current Liabilities
Accounts payable	201	720
Accrued expenses	457	1,090
Total current liabilities	658	1,810
Commitments and Contingencies	0	0
Stockholders’ Equity
Common stock, $0.001 par value; 200,000,000 shares authorized, 6,732,090 and 6,527,900 shares issued and outstanding at September 30, 2020 and March 31, 2020, respectively	7	7
Additional paid-in capital	311,164	306,089
Accumulated deficit	(291,184)	(279,465)
Treasury stock	(1)	0
Total stockholders’ equity	19,986	26,631
Total Liabilities and Stockholders’ Equity	$ 20,644	$ 28,441

Unaudited Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]
Beginning balance at Mar. 31, 2019	$ 36,298	$ 6	$ 297,047	$ 0	$ (260,755)
Beginning balance, Shares at Mar. 31, 2019		6,201,000
Issuance of common stock under employee and director stock option, RSU, and purchase plans	(52)	$ 0	(52)	0	0
Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares		9,000
Issuance of common stock from public offering, net	4,996	$ 0	4,996	0	0
Issuance of common stock from public offering, Shares		304,000
Stock-based compensation expense	1,220	$ 0	1,220	0	0
Net loss	(6,323)	0	0	0	(6,323)
Ending balance at Jun. 30, 2019	36,139	$ 6	303,211	0	(267,078)
Ending balance, Shares at Jun. 30, 2019		6,514,000
Beginning balance at Mar. 31, 2019	36,298	$ 6	297,047	0	(260,755)
Beginning balance, Shares at Mar. 31, 2019		6,201,000
Net loss	(12,617)
Ending balance at Sep. 30, 2019	31,073	$ 6	304,439	0	(273,372)
Ending balance, Shares at Sep. 30, 2019		6,522,000
Beginning balance at Jun. 30, 2019	36,139	$ 6	303,211	0	(267,078)
Beginning balance, Shares at Jun. 30, 2019		6,514,000
Issuance of common stock under employee and director stock option, RSU, and purchase plans	(8)	$ 0	(8)	0	0
Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares		8,000
Stock-based compensation expense	1,236	$ 0	1,236	0	0
Net loss	(6,294)	0	0	0	(6,294)
Ending balance at Sep. 30, 2019	31,073	$ 6	304,439	0	(273,372)
Ending balance, Shares at Sep. 30, 2019		6,522,000
Beginning balance at Mar. 31, 2020	26,631	$ 7	306,089	0	(279,465)
Beginning balance, Shares at Mar. 31, 2020		6,528,000
Issuance of common stock under employee and director stock option, RSU, and purchase plans	(1)	$ 0	(1)	0	0
Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares		3,000
Stock-based compensation expense	925	$ 0	925	0	0
Net loss	(2,769)	0	0	0	(2,769)
Ending balance at Jun. 30, 2020	24,786	$ 7	307,013	0	(282,234)
Ending balance, Shares at Jun. 30, 2020		6,531,000
Beginning balance at Mar. 31, 2020	$ 26,631	$ 7	306,089	0	(279,465)
Beginning balance, Shares at Mar. 31, 2020		6,528,000
Stock option exercises, Shares	2,600
Net loss	$ (11,719)
Ending balance at Sep. 30, 2020	19,986	$ 7	311,164	$ (1)	(291,184)
Ending balance, Shares at Sep. 30, 2020		6,732,000		0
Beginning balance at Jun. 30, 2020	24,786	$ 7	307,013	$ 0	(282,234)
Beginning balance, Shares at Jun. 30, 2020		6,531,000
Stock option exercises	14	$ 0	14	0	0
Stock option exercises, Shares		3,000
Issuance of common stock under employee and director stock option, RSU, and purchase plans	(1)	$ 0	(1)	0	0
Issuance of common stock under employee and director stock option, RSU, and purchase plans, Shares		198,000
Stock-based compensation expense	4,138	$ 0	4,138	0	0
Treasury stock	(1)	0	0	$ (1)	0
Treasury stock, shares				0
Net loss	(8,950)	0	0	$ 0	(8,950)
Ending balance at Sep. 30, 2020	$ 19,986	$ 7	$ 311,164	$ (1)	$ (291,184)
Ending balance, Shares at Sep. 30, 2020		6,732,000		0

Summary of Significant Accounting Policies

6 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Basis of presentation and principles of consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at March 31, 2020 is derived from the Company’s audited consolidated balance sheet at that date.

The unaudited condensed consolidated financial statements include the accounts of Organovo and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2020, as filed with the Securities and Exchange Commission (“SEC”). Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2021 (see “Note 1. Description of Business”).

On August 18, 2020, the Company effected a 1-for-20 reverse stock split of its common stock (the “Reverse Stock Split”). Unless otherwise indicated, all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying condensed consolidated financial statements have, where applicable, been adjusted retroactively to reflect the Reverse Stock Split.

Liquidity

As of September 30, 2020, the Company had cash and cash equivalents of approximately $17.7 million and an accumulated deficit of approximately $291.2 million. The Company also had negative cash flows from operations of approximately $9.7 million during the six months ended September 30, 2020.

Through September 30, 2020, the Company has financed its operations primarily through the sale of convertible notes, warrants, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative agreements, licenses, and grants. During the three and six months ended September 30, 2020, the Company issued no shares of its common stock through its ATM facility.

Throughout the strategic alternatives assessment process, the Company has taken steps to manage its resources and extend its cash runway including selling various assets and reducing its workforce to the minimum level necessary to explore and support these strategic alternatives as well as to support the remainder of the Company’s on-going business activities and assets, including its intellectual property platform and collaborations with research institutions and universities.

The Company believes its cash and cash equivalents on hand will be sufficient to meet its financial obligations for at least the next 12 months of operations. The approval of the Advisory Nominees Proposal triggered a “Change of Control” under the Company’s severance plan, as well as its Directors and Officers (“D&O”) liability insurance policies, which required the following cash outlays: i) approximately $2.8 million for severance obligations; ii) approximately $2.0 million (or $1.7 million net of returned premium) for a six year D&O tail insurance policy; and iii) a new D&O policy premium at approximately $0.8 million. The cash outlays for severance obligations and D&O tail insurance policies were one-time non-recurring expenses that occurred in September 2020 and therefore are reflected in the ending cash balance. In addition, as the Company recommences its operations and is focusing its efforts on drug discovery and development, the Company will need to raise additional capital to implement this new business plan. The Company cannot predict with certainty the exact amount or timing for any future capital raises. If required, the Company may seek to raise additional capital through debt or equity financings, or through some other financing arrangement. However, the Company cannot be sure that additional financing will be available if and when needed, or that, if available, it can obtain financing on terms favorable to its stockholders. Any failure to obtain financing when required will have a material adverse effect on the Company’s business, operating results, financial condition and ability to continue as a going concern.

Use of estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the unaudited condensed consolidated financial statements include those assumed in the valuation of stock-based compensation expense and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions. Though the impact of the COVID-19 pandemic to its business and operating results presents additional uncertainty, the Company continues to use the best information available to inform its critical accounting estimates.

Revenue recognition

The Company has generated revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations.

The Company recognized revenue under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“Topic 606”) when (or as) the promised services were transferred to customers in an amount that reflects the consideration to which it expected to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concluded were within the scope of Topic 606, the Company performed the following five steps: (i) identified the contract(s) with a customer; (ii) identified the performance obligation(s) in the contract; (iii) determined the transaction price; (iv) allocated the transaction price to the performance obligation(s) in the contract; and (v) recognized revenue when (or as) the performance obligation(s) were satisfied. At contract inception, the Company assessed the goods or services promised within each contract, assessed whether each promised good or service was distinct and identified those that were performance obligations. The Company recognized as revenue the amount of the transaction price that was allocated to the respective performance obligation when (or as) the performance obligation was satisfied.

Billings to customers or payments received from customers were included in deferred revenue on the consolidated balance sheet until all revenue recognition criteria were met. As of September 30, 2020 and March 31, 2020, the Company had no deferred revenue.

Service revenues

The Company’s service-based business, Organovo, Inc., previously utilized its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro testing services based on that technology. These contracts with customers contained multiple performance obligations including: (i) bioprinting tissues for the customer, (ii) reporting the results of tests performed on the printed tissues pursuant to the agreed upon work plan through exposure of the tissue to various factors (including the customer’s proprietary compound), and (iii) delivering specific byproduct study materials, which were satisfied, respectively, at each of the following points in time: (i) upon completion of manufacturing of the bioprinted tissue for the customer, (ii) upon delivery of the report on tests performed on the tissue, and (iii) upon making certain study materials generated from the aforementioned testing process available to the customer. The customer did not have access or control of any performance obligation prior to the point in time of full completion of the corresponding performance satisfying event as defined above. Furthermore, although the service could be customized for each customer, it was not so highly customized as to not have an alternative use either to other customers or to the Company without significant economic consequences or rework. Accordingly, the Company’s service-based business utilized point-in-time recognition under Topic 606.

For service contracts, the Company allocated the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price was not observable through past transactions, the Company estimated the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts was a fixed consideration.

In connection with the Company’s decision to pursue its strategic alternatives, the Company halted commercial activities related to its liver tissues. The Company expects to continue to maintain its external research collaborations and its intellectual property portfolio.

Product sales, net

The Company’s former product-based business, Samsara Sciences, Inc., produced high-quality cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognized product revenue when the performance obligation was satisfied, which was at the point in time the customer obtained control of the Company’s product, typically upon delivery. Product revenues were recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration did not differ materially from its historical practices. Variable consideration was estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflected the Company’s best estimates of the amount of consideration to which it was entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may have differed from the Company’s estimates. If actual results varied materially from the Company’s estimates, the Company would have adjusted these estimates, which would have affected revenue from product sales and earnings in the period such estimates were adjusted.

The Company provided no right of return to its customers except in cases where a customer obtained authorization from the Company for the return. To date, there have been no product returns.

In March 2020, the Company dissolved Samsara.

Collaborative research, development, and licenses

The Company has entered into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzed whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC Topic 808, Collaborative Arrangements (“Topic 808”).

The Company considered a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements were distinct performance obligations, whether there were determinable stand-alone prices, and whether any licenses were functional or symbolic. The Company evaluated each performance obligation to determine if it could be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities were considered fixed, while milestone payments were identified as variable consideration which must be evaluated to determine if it was constrained and, therefore, excluded from the transaction price.

The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provided the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company determined that the intellectual property license was not distinct from the continued support promised under the agreement and was therefore a single combined performance obligation. The Company recognized revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation would not be fully satisfied until the end of the contract.

As of September 30, 2019, the Company completed its obligations under the existing agreements with respect to receipts of revenue and does not anticipate recording any further revenue. See “Note 4. Collaborative Research, Development, and License Agreements” for more information on the Company’s collaborative agreements.

Grant revenue

In July 2017, the NIH awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company concluded this government grant was not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company concluded this government grant did meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition did not apply, as the Company is a business entity and the grant was with a governmental agency.

Revenues from this grant were based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue was recognized as the Company incurred expenses that were related to the grant. The Company believes this policy was consistent with the overarching premise in Topic 606, to ensure that it recognized revenues to reflect the transfer of promised goods or services to customers in an amount that reflected the consideration to which it expected to be entitled in exchange for those goods or services, even though there was no “exchange” as defined in the ASC. The Company believed the recognition of revenue as costs were incurred and amounts became earned/realizable was analogous to the concept of transfer of control of a service over time under Topic 606.

In connection with the Company’s decision to pursue its strategic alternatives, specific to the NIH NASH grant, all internal research activities have been halted and transferred to the University of California, San Diego, leaving a remaining available balance of approximately $0.5 million that will not be utilized by the Company.

Cost of revenues

The Company reported no cost of revenues for the three and six months ended September 30, 2020 and approximately $0.3 million in cost of revenues for the three and six months ended September 30, 2019, respectively. Cost of revenues consisted of costs related to manufacturing and delivering product and service revenue.

Net loss per share

Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan (“ESPP”), the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three and six months ended September 30, 2020 or 2019, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive.

Common stock equivalents excluded from computing diluted net loss per share due to their anti-dilutive effect were approximately 0.9 million at September 30, 2020 and 1.0 million at September 30, 2019.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption.

Adoption of New Accounting Pronouncements

In November 2018, the FASB issued Accounting Standard Update (“ASU”) 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 (“ASU 2018-18”), which provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606. ASU 2018-18 provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. The key improvements to GAAP for collaborative arrangements resulting from ASU 2018-18 are to (i) clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit-of-account, (ii) add unit-of-account guidance in Topic 808 to align with the guidance in Topic 606, and (iii) require that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. ASU 2018-18 is effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. This new guidance became effective for the Company on April 1, 2020 and did not have a significant impact on the Company’s unaudited condensed consolidated financial statements.

Restructuring

6 Months Ended

Sep. 30, 2020

Restructuring And Related Activities [Abstract]

Restructuring

Note 9. Restructuring

In August 2019, after a rigorous assessment of the Company’s lead liver therapeutic tissue program following completion of various preclinical studies, the Board concluded that the variability of biological performance and related duration of potential benefits presented development challenges and lengthy redevelopment timelines that no longer supported an attractive opportunity for the Company and its stockholders. Furthermore, the Board deemed the stage of development of the Company’s other therapeutic pipeline assets, including stem cell based tissue programs, to be too premature to potentially reach IND filing status within an acceptable investment horizon and with the Company’s available resources. As a result, the Company suspended all development of its lead program and all other related pipeline development activity and engaged a financial advisory firm to explore its strategic alternatives, including evaluating a range of ways to generate value from the Company’s technology platform and intellectual property, its commercial and development capabilities, its listing on the Nasdaq Capital Market, and its remaining financial assets. Under the restructuring plan, the Company terminated the employment of 52 employees, or 90 percent of its workforce and recorded a restructuring charge during the year ended March 31, 2020 of approximately $2.7 million, related to employee severance and benefits costs, of which approximately $1.7 million was paid out during the second quarter of fiscal 2020, approximately $0.9 million was paid out during the third quarter of fiscal 2020, approximately $0.1 million was paid out during the fourth quarter of fiscal 2020, and less than $0.1 million was paid out during the first quarter of fiscal 2021.

The approval of the Advisory Nominees Proposal in September 2020 triggered a “Change of Control” under the Company’s severance plan. As a result, the Company terminated the employment of its executive officers and recorded a restructuring charge of approximately $2.8 million, related to employee severance and benefits costs, of which approximately $2.6 million was paid out during the second quarter of fiscal 2021. The Company expects to pay approximately $30,000 each quarter through the end of fiscal 2022 as part of the severance and benefit obligations.

Approximately $2.8 million and $2.5 million of restructuring charges were recorded during the three and six months ended September 30, 2020 and 2019, respectively.

	Three Months Ended		Three Months Ended		Six Months Ended		Six Months Ended
	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Severance for Involuntary Employee Terminations	$	2,808	$	2,456	$	2,808	$	2,456
Total Restructuring Expense	$	2,808	$	2,456	$	2,808	$	2,456

The following table summarizes the activity and balances of the restructuring reserve (in thousands):

	Severance for Involuntary Employee Terminations
Balance at March 31, 2020	$	21
Reserve established		—
Increase to reserve		2,808
Utilization of reserve:
Payments		(2,605	)
Balance at September 30, 2020	$	224

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Nov. 01, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Trading Symbol	ONVO
Entity Registrant Name	ORGANOVO HOLDINGS, INC.
Entity Central Index Key	0001497253
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		6,732,090
Entity File Number	001-35996
Entity Current Reporting Status	Yes
Entity Tax Identification Number	27-1488943
Entity Address, Address Line One	440 Stevens Ave
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Solana Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92075
City Area Code	858
Local Phone Number	224-1000
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Stockholders' Equity - Stock Options and Employee Stock Purchase Plan - Additional Information (Detail)	6 Months Ended
	Sep. 30, 2020 USD ($) shares
Class Of Stock [Line Items]
Weighted-average remaining contractual term of options exercisable	10 months 17 days
Weighted-average remaining contractual term of options outstanding	10 months 17 days
Number of common stock shares approved under ESPP	1,166,684
ESPP [Member]
Class Of Stock [Line Items]
Number of common stock shares approved under ESPP	75,000
Employee subscription rate	15.00%
Compensation amount per employee \| $	$ 25,000
Number of shares per employee	500
Fair market value at discount	85.00%
Purchase period	6 months
Initial offering period	2016-09
Description of plan	Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period.
Shares available for purchase under ESPP	59,435

Summary of Significant Accounting Policies - Additional Information (Detail)		1 Months Ended	3 Months Ended		6 Months Ended
	Aug. 18, 2020	Jul. 31, 2017 USD ($)	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 USD ($) shares	Mar. 31, 2020 USD ($) shares
Summary Of Significant Accounting Policies [Line Items]
Conversion ratio	20
Cash and cash equivalents			$ 17,656,000	$ 30,350,000	$ 17,656,000	$ 30,350,000	$ 27,356,000
Accumulated deficit			$ (291,184,000)		(291,184,000)		$ (279,465,000)
Cash flow from operations					$ 9,718,000	11,090,000
Issuance of common stock \| shares			6,732,090		6,732,090		6,527,900
Severance obligations			$ 2,808,000	2,456,000	$ 2,808,000	2,456,000
Deferred revenue			0		0		$ 0
Cost of revenues			0	300,000	0	300,000
Dilutive effect			$ 0	$ 0	$ 0	$ 0
Common stock equivalents excluded from computing diluted net loss per share \| shares					900,000	1,000,000
NIH Research Grants Two [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized under grants		$ 1,657,000
Grant revenue funding period		3 years
Product [Member]
Summary Of Significant Accounting Policies [Line Items]
Product return revenue					$ 0
Grants [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue unutilized remaining available balance					$ 500,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Conversion ratio					40
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Conversion ratio					20
Directors and Officers [Member]
Summary Of Significant Accounting Policies [Line Items]
Severance obligations					$ 2,800,000
New policy premium					800,000
Directors and Officers [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Net of returned insurance premium					2,000,000
Directors and Officers [Member] \| Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Net of returned insurance premium					$ 1,700,000
At-The-Market Facility [Member]
Summary Of Significant Accounting Policies [Line Items]
Issuance of common stock \| shares			0		0

Description of Business

6 Months Ended

Sep. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Description of Business

Note 1. Description of Business

Nature of operations

Organovo Holdings, Inc. (“Organovo,” and “the Company”) is an early-stage biotechnology company that develops highly customized 3D human tissues as living, dynamic models of healthy and diseased human biology for drug development. The Company’s proprietary technology is being used to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. The Company’s advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular structures. The Company believes these attributes can enable critical complex, multicellular disease models that the Company will use to develop clinically effective drugs for selected therapeutic areas. Except where specifically noted or the context otherwise requires, references to “the Company,” and “Organovo” in these notes to the unaudited condensed consolidated financial statements refers to Organovo Holdings, Inc. and its wholly owned subsidiaries, Organovo, Inc. and Opal Merger Sub, Inc.

Historical Operations and Strategic Alternatives Process

Prior to August 2019, the Company has focused its efforts on developing its in vivo liver tissues to treat end-stage liver disease and a select group of life-threatening, orphan diseases, for which there are limited treatment options other than organ transplantation. The Company also explored the development of other potential pipeline in vivo tissue constructs in-house and through collaborations with academic and government researchers. In the past, the Company also explored the development of in vitro tissues, including proof of concept models of diseased tissues, for use in drug discovery and development.

In August 2019, after a rigorous assessment of its in vitro liver therapeutic tissue program, the Company concluded that the variability of biological performance and related duration of potential benefits no longer supported an attractive opportunity due to redevelopment challenges and lengthening timelines to compile sufficient data to support an investigational new drug (“IND”) filing. As a result, the Company suspended development of its lead program and all other related in-house pipeline development activities.

The Company’s Board of Directors (the “Board”) also engaged a financial advisory firm to explore the Company’s available strategic alternatives, including evaluating a range of ways to generate value from its technology platform and intellectual property, its commercial and development capabilities, its listing on the Nasdaq Capital Market, and the Company’s remaining financial assets. These strategic alternatives included possible mergers and business combinations, sales of part or all of its assets, and licensing and partnering arrangements. The Company implemented various restructuring steps to manage its resources and extend its cash runway, including reducing commercial activities related to its liver tissues, except for sales of primary human cells out of inventory, negotiating an exit from its long-term facility lease, selling various assets, and reducing its workforce. Additionally, in November 2019, the Company sold certain inventory and equipment and related proprietary information held by its wholly-owned subsidiary, Samsara Sciences, Inc. (“Samsara”), and as a result of such sale, Samsara ceased its operations.

After conducting a diligent and extensive process of evaluating strategic alternatives and identifying and reviewing potential candidates for a strategic acquisition or other transaction, which included the receipt of more than 27 non-binding indications of interest from interested parties and careful evaluation and consideration of those proposals, and following extensive negotiation with Tarveda Therapeutics, Inc. (“Tarveda”), on December 13, 2019, the Company entered into a merger agreement with Tarveda (the “Merger Agreement”). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, the Company’s wholly-owned merger subsidiary would merge with and into Tarveda (the “Merger”), with Tarveda becoming a wholly-owned subsidiary of Organovo and the surviving corporation of the Merger . The Merger Agreement included various conditions to the consummation of the Merger, including approval by the Company’s stockholders at a Special Meeting of Stockholders to be held on April 7, 2020 (the “Special Meeting”).

At the Special Meeting, the Merger was not approved by the Company’s stockholders. As a result, the Company terminated the Merger Agreement with Tarveda. Pursuant to the terms of the Merger Agreement, the Company was obligated to reimburse certain of Tarveda’s merger-related expenses not to exceed $300,000, which was offset by Tarveda’s portion of shared expenses incurred by Organovo in fiscal 2020.

The Cooperation Agreement and Advisory Nominees Proposal

Following the Special Meeting and the termination of the Merger Agreement, the Board continued to solicit stockholder feedback regarding the Company’s strategic alternatives and how to maximize stockholder value. In response to feedback from its largest stockholder regarding its desire for the Board to consider opportunities in the 3D bioprinting field and suggestion that the Board should speak with Keith Murphy, the Company’s founder, stockholder and former Chief Executive Officer and Chairman, for potential business ideas, the Board initiated discussions with Mr. Murphy. Based on these discussions, the Company entered into a Cooperation Agreement with Mr. Murphy on July 14, 2020 (the “Cooperation Agreement”). Under the terms of the Cooperation Agreement, the Board appointed Mr. Murphy and Adam K. Stern to the Board as Class III directors, and two of the Company’s existing directors, Richard Maroun and David Shapiro, resigned from the Board and all Board committees. The Board also agreed to nominate, recommend, support and solicit proxies for the re-election of Messrs. Murphy and Stern at the Company’s 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”). The Board also agreed to nominate, recommend, support and solicit proxies for an advisory stockholder vote (the “Advisory Nominees Proposal”) at the 2020 Annual Meeting to appoint three individuals, Douglas Jay Cohen, David Gobel and Alison Tjosvold Milhous (collectively, the “Advisory Nominees”), to the Board. Mr. Murphy identified each of the Advisory Nominees. The Board approved the appointment of the Advisory Nominees, to be automatically effective immediately following the final adjournment of the 2020 Annual Meeting if the final vote tabulation for the Advisory Nominees Proposal received more votes cast “FOR” than “AGAINST” its approval. In addition, each of the Company’s then-current directors (other than Messrs. Murphy and Stern) agreed to resign from the Board immediately following the appointment of the Advisory Nominees. At the 2020 Annual Meeting held on September 15, 2020, the Company’s stockholders approved the re-election of Messrs. Murphy and Stern to the Board as Class III directors with votes “For” of 59,229,909 (98.9%) and 59,147,657 (98.8%), respectively, to hold office until the 2023 Annual Meeting of Stockholders. The final vote tabulation for the Advisory Nominees Proposal received more votes cast “FOR” than “AGAINST” its approval, with votes “For” of 54,368,360 (91.4%) and, accordingly, effective upon the final adjournment of the 2020 Annual Meeting, Ms. Milhous was appointed as a Class I director to hold office until the 2021 Annual Meeting of Stockholders and Messrs. Cohen and Gobel were appointed as Class II directors to hold office until the 2022 Annual Meeting (collectively, the “New Director Slate”) and Carolyn Beaver, Taylor Crouch, Mark Kessel and Kirk Malloy, Ph.D. each resigned as directors.

COVID-19

In December 2019 a respiratory illness caused by a novel strain of coronavirus, SARS-CoV-2, causing the Coronavirus Disease 2019, also known as COVID-19 or coronavirus emerged. While initially the outbreak was largely concentrated in China, it has since spread globally and been declared a pandemic by the World Health Organization. Global health concerns relating to the COVID-19 pandemic have been weighing on the macroeconomic environment, and the pandemic has significantly increased economic volatility and uncertainty. The pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns.

The extent to which the coronavirus impacts the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak and travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. In particular, the continued coronavirus pandemic could adversely impact the Company’s operations, including among others, the timing and ability to pursue its strategy, given the impact it may have on the manufacturing and supply chain, sales and marketing and clinical trial operations of potential strategic partners, and the ability to advance its research and development activities and pursue development of its pipeline products, each of which could have an adverse impact on the Company’s business and financial results.

Stockholders' Equity (Tables)

6 Months Ended

Sep. 30, 2020

Class Of Stock [Line Items]

Schedule of Stock-based Compensation Expense

Stock-based compensation expense for all stock-based awards consists of the following (in thousands):

	Three Months Ended		Three Months Ended		Six Months Ended		Six Months Ended
	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Research and development	$	7	$	10	$	7	$	174
General and administrative	$	4,131	$	1,226	$	5,056	$	2,282
Total	$	4,138	$	1,236	$	5,063	$	2,456

Fair Value of Employee Stock Options

The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

	Three Months Ended			Three Months Ended			Six Months Ended			Six Months Ended
	September 30, 2020			September 30, 2019			September 30, 2020			September 30, 2019
Dividend yield		—			—			—			—
Volatility		108.39	%		84.36	%		108.39	%		84.36	%
Risk-free interest rate		0.27	%		1.53	%		0.27	%		1.53	%
Expected life of options	6.00 years			6.00 years			6.00 years			6.00 years
Weighted average grant date fair value	$	6.22		$	4.60		$	6.22		$	4.60

Fair Value of Employee Stock Purchase Plan

The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions:

	Three Months Ended			Three Months Ended			Six Months Ended			Six Months Ended
	September 30, 2020*			September 30, 2019			September 30, 2020*			September 30, 2019
Dividend yield		—			—			—			—
Volatility		0.00	%		43.69	%		0.00	%		43.69	%
Risk-free interest rate		0.00	%	2.52				0.00	%	2.52
Expected term	0 months			6 months			0 months			6 months
Grant date fair value	$	-		$	5.80		$	-		$	5.80

*There were no participants in the ESPP for the purchase period beginning March 1, 2020 and the current purchase period (beginning September 1, 2020).

Summary of Stock Option Activity

The following table summarizes the Company’s stock option activity from March 31, 2020 to September 30, 2020:

	Options Outstanding			Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at March 31, 2020		377,980		$	41.81	$	37,440
Options granted		466,875		$	7.61	$	—
Options cancelled / forfeited		—		$	—	$	—
Options exercised		(2,600	)	$	5.32	$	8,580
Outstanding at September 30, 2020		842,255		$	22.96	$	168,742
Vested and Exercisable at September 30, 2020		375,380		$	42.06	$	26,936

Common Stock Reserved for Future Issuance

Common stock reserved for future issuance consisted of the following at September 30, 2020:

Common stock options outstanding and reserved under the 2012 Plan			737,845
Common stock reserved under the 2012 Plan			251,026
Common stock reserved under the ESPP			59,435
Restricted stock units outstanding under the 2012 Plan			1,739
Performance-based restricted stock units outstanding under the 2012 Plan			12,229
Common stock options outstanding and reserved under the Inducement Award Agreement			104,410
Total at September 30, 2020			1,166,684

Restricted stock units (RSUs) [Member]

Class Of Stock [Line Items]

Summary of Company's Restricted Stock Units Activity and Performance Based Restricted Stock Units Activity

The following table summarizes the Company’s restricted stock units (not including performance-based restricted stock units) activity from March 31, 2020 through September 30, 2020:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2020		18,116		$	43.49
Granted		—		$	—
Vested		(16,377	)	$	45.83
Cancelled / forfeited		—		$	—
Unvested at September 30, 2020		1,739		$	21.46

Performance-Based Restricted Stock Units [Member]

Class Of Stock [Line Items]

Summary of Company's Restricted Stock Units Activity and Performance Based Restricted Stock Units Activity

The following table summarizes the Company’s performance-based restricted stock unit activity from March 31, 2020 through September 30, 2020:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2020		197,644		$	10.24
Granted		—		$	—
Vested		(185,415	)	$	10.27
Cancelled / forfeited		—		$	—
Unvested at September 30, 2020		12,229		$	9.80

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not necessarily include all information and notes required by GAAP for complete financial statements. The condensed consolidated balance sheet at March 31, 2020 is derived from the Company’s audited consolidated balance sheet at that date. The unaudited condensed consolidated financial statements include the accounts of Organovo and its wholly owned subsidiaries. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited financial information for the interim periods presented reflects all adjustments, which are only normal and recurring, necessary for a fair statement of the Company’s financial position, results of operations, stockholders’ equity and cash flows. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2020, as filed with the Securities and Exchange Commission (“SEC”). Operating results for interim periods are not necessarily indicative of operating results for the Company’s fiscal year ending March 31, 2021 (see “Note 1. Description of Business”). On August 18, 2020, the Company effected a 1-for-20 reverse stock split of its common stock (the “Reverse Stock Split”). Unless otherwise indicated, all share amounts, per share data, share prices, exercise prices and conversion rates set forth in these notes and the accompanying condensed consolidated financial statements have, where applicable, been adjusted retroactively to reflect the Reverse Stock Split.
Liquidity	Liquidity As of September 30, 2020, the Company had cash and cash equivalents of approximately $17.7 million and an accumulated deficit of approximately $291.2 million. The Company also had negative cash flows from operations of approximately $9.7 million during the six months ended September 30, 2020. Through September 30, 2020, the Company has financed its operations primarily through the sale of convertible notes, warrants, the private placement of equity securities, the sale of common stock through public and at-the-market (“ATM”) offerings, and through revenue derived from product and research service-based agreements, collaborative agreements, licenses, and grants. During the three and six months ended September 30, 2020, the Company issued no shares of its common stock through its ATM facility. Throughout the strategic alternatives assessment process, the Company has taken steps to manage its resources and extend its cash runway including selling various assets and reducing its workforce to the minimum level necessary to explore and support these strategic alternatives as well as to support the remainder of the Company’s on-going business activities and assets, including its intellectual property platform and collaborations with research institutions and universities. The Company believes its cash and cash equivalents on hand will be sufficient to meet its financial obligations for at least the next 12 months of operations. The approval of the Advisory Nominees Proposal triggered a “Change of Control” under the Company’s severance plan, as well as its Directors and Officers (“D&O”) liability insurance policies, which required the following cash outlays: i) approximately $2.8 million for severance obligations; ii) approximately $2.0 million (or $1.7 million net of returned premium) for a six year D&O tail insurance policy; and iii) a new D&O policy premium at approximately $0.8 million. The cash outlays for severance obligations and D&O tail insurance policies were one-time non-recurring expenses that occurred in September 2020 and therefore are reflected in the ending cash balance. In addition, as the Company recommences its operations and is focusing its efforts on drug discovery and development, the Company will need to raise additional capital to implement this new business plan. The Company cannot predict with certainty the exact amount or timing for any future capital raises. If required, the Company may seek to raise additional capital through debt or equity financings, or through some other financing arrangement. However, the Company cannot be sure that additional financing will be available if and when needed, or that, if available, it can obtain financing on terms favorable to its stockholders. Any failure to obtain financing when required will have a material adverse effect on the Company’s business, operating results, financial condition and ability to continue as a going concern.
Use of estimates	The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates used in preparing the unaudited condensed consolidated financial statements include those assumed in the valuation of stock-based compensation expense and the valuation allowance on deferred tax assets. On an ongoing basis, management reviews these estimates and assumptions. Though the impact of the COVID-19 pandemic to its business and operating results presents additional uncertainty, the Company continues to use the best information available to inform its critical accounting estimates.
Revenue recognition	Revenue recognition The Company has generated revenues from payments received from research service agreements, product sales, collaborative agreements with partners including pharmaceutical and biotechnology companies and academic institutions, licenses, and grants from the National Institutes of Health (“NIH”) and private not-for-profit organizations. The Company recognized revenue under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“Topic 606”) when (or as) the promised services were transferred to customers in an amount that reflects the consideration to which it expected to be entitled in exchange for those services. To determine revenue recognition for arrangements the Company concluded were within the scope of Topic 606, the Company performed the following five steps: (i) identified the contract(s) with a customer; (ii) identified the performance obligation(s) in the contract; (iii) determined the transaction price; (iv) allocated the transaction price to the performance obligation(s) in the contract; and (v) recognized revenue when (or as) the performance obligation(s) were satisfied. At contract inception, the Company assessed the goods or services promised within each contract, assessed whether each promised good or service was distinct and identified those that were performance obligations. The Company recognized as revenue the amount of the transaction price that was allocated to the respective performance obligation when (or as) the performance obligation was satisfied. Billings to customers or payments received from customers were included in deferred revenue on the consolidated balance sheet until all revenue recognition criteria were met. As of September 30, 2020 and March 31, 2020, the Company had no deferred revenue. Service revenues The Company’s service-based business, Organovo, Inc., previously utilized its NovoGen® bioprinting platform to provide customers access to its highly specialized tissues that model human biology and disease, and to in vitro testing services based on that technology. These contracts with customers contained multiple performance obligations including: (i) bioprinting tissues for the customer, (ii) reporting the results of tests performed on the printed tissues pursuant to the agreed upon work plan through exposure of the tissue to various factors (including the customer’s proprietary compound), and (iii) delivering specific byproduct study materials, which were satisfied, respectively, at each of the following points in time: (i) upon completion of manufacturing of the bioprinted tissue for the customer, (ii) upon delivery of the report on tests performed on the tissue, and (iii) upon making certain study materials generated from the aforementioned testing process available to the customer. The customer did not have access or control of any performance obligation prior to the point in time of full completion of the corresponding performance satisfying event as defined above. Furthermore, although the service could be customized for each customer, it was not so highly customized as to not have an alternative use either to other customers or to the Company without significant economic consequences or rework. Accordingly, the Company’s service-based business utilized point-in-time recognition under Topic 606. For service contracts, the Company allocated the transaction price to each performance obligation based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. If the standalone selling price was not observable through past transactions, the Company estimated the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The transaction price for service business contracts was a fixed consideration. In connection with the Company’s decision to pursue its strategic alternatives, the Company halted commercial activities related to its liver tissues. The Company expects to continue to maintain its external research collaborations and its intellectual property portfolio. Product sales, net The Company’s former product-based business, Samsara Sciences, Inc., produced high-quality cell-based products for use in Organovo’s 3D tissue manufacturing and for use by life science customers. The Company recognized product revenue when the performance obligation was satisfied, which was at the point in time the customer obtained control of the Company’s product, typically upon delivery. Product revenues were recorded at the transaction price, net of any estimates for variable consideration under Topic 606. The Company’s process for estimating variable consideration did not differ materially from its historical practices. Variable consideration was estimated using the expected value method which considers the sum of probability-weighted amounts in a range of possible amounts under the contract. Product revenue reflected the Company’s best estimates of the amount of consideration to which it was entitled based on the terms of the individual contracts. Actual amounts of consideration ultimately received may have differed from the Company’s estimates. If actual results varied materially from the Company’s estimates, the Company would have adjusted these estimates, which would have affected revenue from product sales and earnings in the period such estimates were adjusted. The Company provided no right of return to its customers except in cases where a customer obtained authorization from the Company for the return. To date, there have been no product returns. In March 2020, the Company dissolved Samsara. Collaborative research, development, and licenses The Company has entered into collaborative agreements with partners that typically include one or more of the following: (i) non-exclusive license fees; (ii) non-refundable up-front fees; (iii) payments for reimbursement of research costs; (iv) payments associated with achieving specific development milestones; and (v) royalties based on specified percentages of net product sales, if any. At the initiation of an agreement, the Company analyzed whether it results in a contract with a customer under Topic 606 or in an arrangement with a collaborator subject to guidance under ASC Topic 808, Collaborative Arrangements (“Topic 808”). The Company considered a variety of factors in determining the appropriate estimates and assumptions under these arrangements, such as whether the elements were distinct performance obligations, whether there were determinable stand-alone prices, and whether any licenses were functional or symbolic. The Company evaluated each performance obligation to determine if it could be satisfied and recognized as revenue at a point in time or over time. Typically, non-exclusive license fees, non-refundable upfront fees, and funding of research activities were considered fixed, while milestone payments were identified as variable consideration which must be evaluated to determine if it was constrained and, therefore, excluded from the transaction price. The Company’s collaborative agreements that were not completed at the implementation of Topic 606 on April 1, 2018, consisted of research collaboration and limited technology access licenses. These agreements provided the licensee with a non-exclusive, non-transferable, limited, royalty-free technology license, including access to Organovo’s proprietary bioprinter platform, training, and continued support by means of consumables and consultation throughout the duration of the contract. The Company determined that the intellectual property license was not distinct from the continued support promised under the agreement and was therefore a single combined performance obligation. The Company recognized revenue for these combined performance obligations over time for the duration of the license period, as the combined performance obligation would not be fully satisfied until the end of the contract. As of September 30, 2019, the Company completed its obligations under the existing agreements with respect to receipts of revenue and does not anticipate recording any further revenue. See “Note 4. Collaborative Research, Development, and License Agreements” for more information on the Company’s collaborative agreements. Grant revenue In July 2017, the NIH awarded the Company a “Research and Development” grant totaling approximately $1,657,000 of funding over three years. The Company concluded this government grant was not within the scope of Topic 606, as government entities do not meet the definition of a “customer” as defined by Topic 606, as there is not considered to be a transfer of control of goods or services to the government entity funding the grant. Additionally, the Company concluded this government grant did meet the definition of a contribution and is a non-reciprocal transaction, however, Subtopic 958-605, Not-for-Profit-Entities-Revenue Recognition did not apply, as the Company is a business entity and the grant was with a governmental agency. Revenues from this grant were based upon internal costs incurred that are specifically covered by the grant, plus an additional rate that provides funding for overhead expenses. Revenue was recognized as the Company incurred expenses that were related to the grant. The Company believes this policy was consistent with the overarching premise in Topic 606, to ensure that it recognized revenues to reflect the transfer of promised goods or services to customers in an amount that reflected the consideration to which it expected to be entitled in exchange for those goods or services, even though there was no “exchange” as defined in the ASC. The Company believed the recognition of revenue as costs were incurred and amounts became earned/realizable was analogous to the concept of transfer of control of a service over time under Topic 606. In connection with the Company’s decision to pursue its strategic alternatives, specific to the NIH NASH grant, all internal research activities have been halted and transferred to the University of California, San Diego, leaving a remaining available balance of approximately $0.5 million that will not be utilized by the Company.
Cost of revenues	Cost of revenues The Company reported no cost of revenues for the three and six months ended September 30, 2020 and approximately $0.3 million in cost of revenues for the three and six months ended September 30, 2019, respectively. Cost of revenues consisted of costs related to manufacturing and delivering product and service revenue.
Net loss per share	Net loss per share Basic and diluted net loss per share has been computed using the weighted-average number of shares of common stock outstanding during the period. The weighted-average number of shares used to compute diluted loss per share excludes any assumed exercise of stock options, shares reserved for purchase under the Company’s 2016 Employee Stock Purchase Plan (“ESPP”), the assumed release of restriction of restricted stock units, and shares subject to repurchase as the effect would be anti-dilutive. No dilutive effect was calculated for the three and six months ended September 30, 2020 or 2019, as the Company reported a net loss for each respective period and the effect would have been anti-dilutive. Common stock equivalents excluded from computing diluted net loss per share due to their anti-dilutive effect were approximately 0.9 million at September 30, 2020 and 1.0 million at September 30, 2019.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies. Unless otherwise stated, the Company believes that the impact of the recently issued accounting pronouncements that are not yet effective will not have a material impact on its consolidated financial position or results of operations upon adoption. Adoption of New Accounting Pronouncements In November 2018, the FASB issued Accounting Standard Update (“ASU”) 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606 (“ASU 2018-18”), which provides guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606. ASU 2018-18 provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. The key improvements to GAAP for collaborative arrangements resulting from ASU 2018-18 are to (i) clarify that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit-of-account, (ii) add unit-of-account guidance in Topic 808 to align with the guidance in Topic 606, and (iii) require that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. ASU 2018-18 is effective for all entities for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years with early adoption permitted. This new guidance became effective for the Company on April 1, 2020 and did not have a significant impact on the Company’s unaudited condensed consolidated financial statements.

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

+ Details

Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues
Total Revenues	$ 0	$ 1,230	$ 0	$ 1,898
Cost of revenues	0	264	0	315
Research and development expenses	28	1,445	28	5,268
Selling, general and administrative expenses	8,922	6,348	11,708	9,663
Total costs and expenses	8,950	8,057	11,736	15,246
Loss from Operations	(8,950)	(6,827)	(11,736)	(13,348)
Other Income (Expense)
Gain (loss) on fixed asset disposals	(5)	85	1	86
Interest income	4	183	12	380
Other income	1	267	6	267
Total Other Income	0	535	19	733
Income Tax Expense	0	(2)	(2)	(2)
Net Loss	$ (8,950)	$ (6,294)	$ (11,719)	$ (12,617)
Net loss per common share—basic and diluted	$ (1.36)	$ (1.00)	$ (1.79)	$ (2.00)
Weighted average shares used in computing net loss per common share—basic and diluted	6,565,245	6,517,859	6,547,430	6,430,781
Comprehensive Loss:
Net loss	$ (8,950)	$ (6,294)	$ (11,719)	$ (12,617)
Comprehensive loss	(8,950)	(6,294)	(11,719)	(12,617)
Products and Services [Member]
Revenues
Total Revenues	0	1,221	0	1,827
Collaborations and Licenses [Member]
Revenues
Total Revenues	0	9	0	19
Grants [Member]
Revenues
Total Revenues	$ 0	$ 0	$ 0	$ 52

Stockholders' Equity

6 Months Ended

Sep. 30, 2020

Equity [Abstract]

Stockholders' Equity

Note 3. Stockholders’ Equity

Stock-based compensation expense and valuation information

Stock-based awards include stock options and restricted stock units under the 2012 Equity Incentive Plan, as amended (“2012 Plan”) and Inducement Awards, performance-based restricted stock units under an Incentive Award Performance-Based Restricted Stock Unit Agreement, and rights to purchase stock under the ESPP. The Company calculates the grant date fair value of all stock-based awards in determining the stock-based compensation expense.

Stock-based compensation expense for all stock-based awards consists of the following (in thousands):

	Three Months Ended		Three Months Ended		Six Months Ended		Six Months Ended
	September 30, 2020		September 30, 2019		September 30, 2020		September 30, 2019
Research and development	$	7	$	10	$	7	$	174
General and administrative	$	4,131	$	1,226	$	5,056	$	2,282
Total	$	4,138	$	1,236	$	5,063	$	2,456

The total unrecognized compensation cost related to unvested stock option grants as of September 30, 2020 was approximately $2,866,000 and the weighted average period over which these grants are expected to vest is 3.59 years.

The total unrecognized compensation cost related to unvested restricted stock units (not including performance-based restricted stock units) as of September 30, 2020 was approximately $35,000, which will be recognized over a weighted average period of 2.14 years.

The total unrecognized compensation cost related to unvested performance-based restricted stock units as of September 30, 2020 was approximately $45,000, which will be recognized over a weighted average period of 0.75 years.

As of September 30, 2020, there are no participants enrolled in the employee stock purchase plan for the current purchase period, beginning September 1, 2020.

The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

	Three Months Ended			Three Months Ended			Six Months Ended			Six Months Ended
	September 30, 2020			September 30, 2019			September 30, 2020			September 30, 2019
Dividend yield		—			—			—			—
Volatility		108.39	%		84.36	%		108.39	%		84.36	%
Risk-free interest rate		0.27	%		1.53	%		0.27	%		1.53	%
Expected life of options	6.00 years			6.00 years			6.00 years			6.00 years
Weighted average grant date fair value	$	6.22		$	4.60		$	6.22		$	4.60

The assumed dividend yield is based on the Company’s expectation of not paying dividends in the foreseeable future. The Company uses the Company-specific historical volatility rate as the indicator of expected volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options. The measurement and classification of share-based payments to non-employees is consistent with the measurement and classification of share-based payments to employees.

The fair value of each restricted stock unit and performance-based restricted stock unit is recognized as stock-based compensation expense over the vesting term of the award. The fair value is based on the closing stock price on the date of the grant.

The Company uses the Black-Scholes valuation model to calculate the fair value of shares issued pursuant to the ESPP. Stock-based compensation expense is recognized over the purchase period using the straight-line method. The fair value of ESPP shares was estimated at the purchase period commencement date using the following assumptions:

	Three Months Ended			Three Months Ended			Six Months Ended			Six Months Ended
	September 30, 2020*			September 30, 2019			September 30, 2020*			September 30, 2019
Dividend yield		—			—			—			—
Volatility		0.00	%		43.69	%		0.00	%		43.69	%
Risk-free interest rate		0.00	%	2.52				0.00	%	2.52
Expected term	0 months			6 months			0 months			6 months
Grant date fair value	$	-		$	5.80		$	-		$	5.80

*There were no participants in the ESPP for the purchase period beginning March 1, 2020 and the current purchase period (beginning September 1, 2020).

The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. The Company uses the Company-specific historical volatility rate as the indicator of expected volatility. The risk-free interest rate assumption was based on U.S. Treasury rates. The expected life is the 6-month purchase period.

Preferred stock

The Company is authorized to issue 25,000,000 shares of preferred stock. There are no shares of preferred stock currently outstanding, and the Company has no current plans to issue shares of preferred stock.

Common stock

On June 25, 2019, the Company received a notice letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum closing bid price of $1 per share, as set forth in Nasdaq Listing Rule 5450(a)(1). On December 26, 2019, the Company obtained an additional compliance period of 180 calendar days by electing to transfer to The Nasdaq Capital Market. On March 26, 2020, the Company obtained shareholder approval to effect a reverse stock split in a range from 20:1 to 40:1 in order to meet the minimum closing bid price per share requirement under the Nasdaq Listing Rules.

On April 17, 2020, the Company received an additional notice letter from Nasdaq indicating that based on extraordinary market conditions, Nasdaq has determined to toll the compliance periods for bid price and market value of publicly held shares requirements (collectively, the “Price-based Requirements”) through June 30, 2020. Accordingly, since the Company had 66 calendar days remaining in its compliance period as of April 16, 2020, the Company had until September 4, 2020 to regain compliance. On August 18, 2020, the Company effected the Reverse Stock Split with a ratio of 20:1, and on September 2, 2020, the Company received notification from Nasdaq that the closing bid price of its common stock had been at $1.00 per share or greater for ten consecutive business days and that Nasdaq had closed the matter. There can be no assurance that the Company will be able to maintain compliance with the Price-based Requirements or other listing requirements necessary to maintain the listing of its common stock on the Nasdaq Capital Market.

The Company has an effective shelf registration statement on Form S-3 (File No. 333-222929) and the related prospectus previously declared effective by the Securities and Exchange Commission (the “SEC”) on February 22, 2018 (the “2018 Shelf”), that expires on February 22, 2021, which registered $100,000,000 of common stock, preferred stock, warrants and units, or any combination of the foregoing.

On March 16, 2018, the Company entered into a Sales Agreement (“2018 Sales Agreement”) with H.C. Wainwright & Co., LLC and Jones Trading Institutional Services LLC (each an “Agent” and together, the “Agents”) and filed a prospectus supplement to the 2018 Shelf, pursuant to which the Company may offer and sell, from time to time through the Agents, shares of its common stock in at-the-market sales transactions having an aggregate offering price of up to $50,000,000 (the “Shares”). Any shares offered and sold will be issued pursuant to the Company’s 2018 Shelf.

During the six months ended September 30, 2020 and 2019, the Company issued 0 and 304,369 shares of common stock, respectively, for net proceeds of $0 and $5.0 million in at-the-market offerings under the 2018 Sales Agreement.

As of September 30, 2020, the Company has sold an aggregate of 885,959 shares of common stock in at-the-market offerings under the 2018 Sales Agreement, with gross proceeds of approximately $18.7 million. Based on these sales, the Company cannot raise more than an aggregate of $81.3 million in future offerings under the 2018 Shelf, including the $31.3 million remaining available for future issuance through its at-the-market program under the 2018 Sales Agreement.

During the three and six months ended September 30, 2020 and 2019, the Company issued 2,600 and 0 shares of common stock upon the exercise of stock options, respectively.

Restricted stock units

The following table summarizes the Company’s restricted stock units (not including performance-based restricted stock units) activity from March 31, 2020 through September 30, 2020:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2020		18,116		$	43.49
Granted		—		$	—
Vested		(16,377	)	$	45.83
Cancelled / forfeited		—		$	—
Unvested at September 30, 2020		1,739		$	21.46

Performance-based restricted stock units

On April 24, 2017, the Company issued a Performance-Based Restricted Stock Unit Award for 10,441 shares of common stock (the “PBRSU”) to its then-newly hired Chief Executive Officer. The PBRSU was issued outside of the 2012 Plan, in the Inducement Award Agreement, as an “inducement award” within the meaning of Nasdaq Marketplace Rule 5635(c)(4). While outside the Company’s 2012 Plan, the terms and conditions of the awards are consistent with awards granted to the Company’s executive officers pursuant to the 2012 Plan. On August 23, 2017, the Board formally approved the vesting criteria for the PBRSU. The vesting of the PBRSU is divided into five separate tranches each with independent vesting criteria. The first four tranches had performance criteria related to annual revenue goals with measurement at the end of fiscal year 2018 (20 percent), fiscal year 2019 (20 percent), fiscal year 2020 (20 percent), and fiscal year 2021 (20 percent). The fifth tranche had a performance metric related to a path to profitability goal measured as Negative Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) achievable at any point between the grant date and the end of fiscal year 2020 (20 percent). The number of units that ultimately vest for each tranche will range from 0 percent to 120 percent of the target amount, not to exceed 10,441 in aggregate. On December 12, 2018, the Board formally approved an amendment to the vesting criteria for the PBRSUs. As of December 12, 2018, 100 percent of the Negative Adjusted EBITDA tranche, or 2,088 shares had vested and 418 units had been forfeited. Based on the amendment to the vesting criteria, the remaining 7,935 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones.

Based on the amended PBRSU vesting terms, a Type III modification, the modified grant date fair value of the PBRSUs is $165,000 of which one-third is being recognized over the expected service period of each tranche ending on April 23, 2023. The Company began recording stock-based compensation expense for the initial performance tranches after the August 23, 2017 grant date when the initial financial performance goals were established and approved and has modified its recording of compensation expense in accordance with the amended performance tranches beginning on December 12, 2018. As of September 30, 2020, all tranches accelerated vesting due to a change in control.

On July 2, 2019, the Company issued Performance-Based Restricted Stock Unit Awards (the “PBRSU Retention Awards”) for an aggregate of 301,391 shares of common stock to its management team. The PBRSUs were issued pursuant to the 2012 Plan. The PBRSU Retention Awards will vest in full upon the earlier of the Company’s engagement in a pre-IND meeting with the FDA, twenty-four months from the grant date, or a change in control. As of September 30, 2020, 111,682 shares forfeited due to terminations and 177,480 shares accelerated vesting due to a change in control. The remaining 12,229 shares are expected to vest twenty-four months from the grant date as these particular shares require two of the conditions to be met in order to vest.

The following table summarizes the Company’s performance-based restricted stock unit activity from March 31, 2020 through September 30, 2020:

	Number of Shares			Weighted Average Price
Unvested at March 31, 2020		197,644		$	10.24
Granted		—		$	—
Vested		(185,415	)	$	10.27
Cancelled / forfeited		—		$	—
Unvested at September 30, 2020		12,229		$	9.80

Stock options

The following table summarizes the Company’s stock option activity from March 31, 2020 to September 30, 2020:

	Options Outstanding			Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding at March 31, 2020		377,980		$	41.81	$	37,440
Options granted		466,875		$	7.61	$	—
Options cancelled / forfeited		—		$	—	$	—
Options exercised		(2,600	)	$	5.32	$	8,580
Outstanding at September 30, 2020		842,255		$	22.96	$	168,742
Vested and Exercisable at September 30, 2020		375,380		$	42.06	$	26,936

The weighted average remaining contractual term of options exercisable and outstanding at September 30, 2020 was approximately 0.88 years.

Employee Stock Purchase Plan

In June 2016, the Board adopted, and in August 2016, the Company’s stockholders subsequently approved, the ESPP. The Company reserved 75,000 shares of common stock for issuance thereunder. The ESPP permits employees after five months of service to purchase common stock through payroll deductions, limited to 15 percent of each employee’s compensation up to $25,000 per employee per year or 500 shares per employee per six-month purchase period. Shares under the ESPP are purchased at 85 percent of the fair market value at the lower of (i) the closing price on the first trading day of the six-month purchase period or (ii) the closing price on the last trading day of the six-month purchase period. The initial offering period commenced in September 2016. At September 30, 2020, there were 59,435 shares available for purchase under the ESPP.

Common stock reserved for future issuance

Common stock reserved for future issuance consisted of the following at September 30, 2020:

Common stock options outstanding and reserved under the 2012 Plan			737,845
Common stock reserved under the 2012 Plan			251,026
Common stock reserved under the ESPP			59,435
Restricted stock units outstanding under the 2012 Plan			1,739
Performance-based restricted stock units outstanding under the 2012 Plan			12,229
Common stock options outstanding and reserved under the Inducement Award Agreement			104,410
Total at September 30, 2020			1,166,684

Treasury stock

Repurchased shares of common stock are recorded as treasury stock, at cost, but may from time to time be retired. Following the Reverse Stock Split in August 2020, the Company purchased 46 shares of treasury stock at cost of less than $0.1 million related to the funding of cash payments in lieu of the issuance of fractional shares.

Stockholders' Equity - Restricted Stock Awards, Restricted Stock Units and Performance-Based Restricted Stock Units - Additional Information (Detail)				6 Months Ended
	Jul. 02, 2019 shares	Dec. 12, 2018 shares	Aug. 23, 2017 USD ($) Tranche shares	Sep. 30, 2020 shares	Apr. 24, 2017 shares
Inducement Award Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Number of tranches \| Tranche			5
Award vesting percentage		100.00%
Grant date fair values of tranches \| $			$ 165,000
Inducement Award Performance-Based Restricted Stock Units [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Number of shares allocated			10,441
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche One [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2018
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche One [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche One [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Two [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2019
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Two [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Two [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Three [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2020
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Three [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share-based Compensation Award, Tranche Three [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Four [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2021
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Four [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Four [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Five [Member]
Class Of Stock [Line Items]
Award vesting percentage			20.00%
Stock units vesting year			2020
Share based compensation arrangement, number of shares vested		2,088
Share based compensation arrangement, number of shares forfeited		418
Share based compensation arrangement, number of shares eligible to vest upon future performance				7,935
Share based compensation arrangement amendment description and terms				Based on the amendment to the vesting criteria, the remaining 7,935 units eligible to vest upon future performance were divided into three separate but equal tranches with independent vesting criteria based on the achievement of certain regulatory milestones.
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Five [Member] \| Minimum [Member]
Class Of Stock [Line Items]
Award vesting percentage			0.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| Share Based Compensation Award Tranche Five [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Award vesting percentage			120.00%
Inducement Award Performance-Based Restricted Stock Units [Member] \| CEO [Member]
Class Of Stock [Line Items]
Number of shares allocated					10,441
PBRSU Retention Awards [Member] \| Management Team [Member]
Class Of Stock [Line Items]
Number of shares allocated	301,391
Vesting period	24 months			24 months
Shares forfeited due to terminations				111,682
Shares accelerated vesting due to a change in control				177,480
Shares that are expected to vest				12,229

Stockholders' Equity - Common Stock - Additional Information (Detail)				3 Months Ended		6 Months Ended
	Sep. 02, 2020 $ / shares	Aug. 18, 2020	Jun. 25, 2019 $ / shares	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 shares	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 USD ($) shares	Mar. 31, 2020 shares	Mar. 16, 2018 USD ($)
Class Of Stock [Line Items]
Reverse stock split						20:1 to 40:1
Conversion ratio		20
Issuance of common stock from stock options exercises, net, Shares \| shares				2,600	0	2,600	0
Issuance of common stock \| shares				6,732,090		6,732,090		6,527,900
Minimum [Member]
Class Of Stock [Line Items]
Minimum closing bid price \| $ / shares	$ 1		$ 1
Conversion ratio						20
Maximum [Member]
Class Of Stock [Line Items]
Conversion ratio						40
2018 Sales Agreement [Member]
Class Of Stock [Line Items]
Equity sales agreement expiration date						Feb. 22, 2021
Value of shares sold under equity distribution agreement						$ 18,700,000
Issuance of common stock \| shares				885,959		885,959
2018 Sales Agreement [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Common stock value reserved for future issuance				$ 81,300,000		$ 81,300,000
IPO [Member]
Class Of Stock [Line Items]
Securities authorized for offer and sale, amount				$ 100,000,000		$ 100,000,000
At-The-Market Facility [Member]
Class Of Stock [Line Items]
Issuance of common stock \| shares				0		0
At-The-Market Facility [Member] \| 2018 Sales Agreement [Member]
Class Of Stock [Line Items]
Common stock value reserved for future issuance				$ 31,300,000		$ 31,300,000
Issuance of common stock from stock options exercises, net, Shares \| shares						0	304,369
Value of shares sold under equity distribution agreement						$ 0	$ 5,000,000
At-The-Market Facility [Member] \| 2018 Sales Agreement [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Common stock value reserved for future issuance									$ 50,000,000

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash Flows From Operating Activities
Net loss	$ (11,719)	$ (12,617)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain (loss) on disposal of fixed assets	1	(85)
Depreciation and amortization	8	379
Stock-based compensation	5,063	2,456
Inventory write-off	0	214
Increase (decrease) in cash resulting from changes in:
Accounts receivable	92	(116)
Grants receivable	0	55
Inventory	0	(75)
Prepaid expenses and other assets	(2,011)	415
Accounts payable	(519)	(476)
Accrued expenses	(633)	(617)
Deferred revenue	0	(525)
Operating lease right-of-use assets and liabilities, net	0	(98)
Net cash used in operating activities	(9,718)	(11,090)
Cash Flows From Investing Activities
Proceeds from disposals of fixed assets	7	27
Net cash provided by investing activities	7	27
Cash Flows From Financing Activities
Proceeds from issuance of common stock, net	0	4,996
Employee taxes paid related to net share settlement of equity awards	(2)	(60)
Proceeds from exercise of stock options	14	0
Purchase of treasury stock	(1)	0
Net cash provided by financing activities	11	4,936
Net decrease in cash, cash equivalents, and restricted cash	(9,700)	(6,127)
Cash, cash equivalents, and restricted cash at beginning of period	27,356	36,556
Cash, cash equivalents, and restricted cash at end of period	17,656	30,429
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	17,656	30,350
Restricted cash	0	79
Cash, cash equivalents, and restricted cash at end of period	17,656	30,429
Supplemental Disclosure of Cash Flow Information:
Fixed asset reclass	31	0
Income taxes paid	$ 2	$ 2

Stockholders' Equity - Summary of Stock Option Activity (Detail) - USD ($)	6 Months Ended
	Sep. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Options Outstanding, Beginning balance	377,980
Granted, Options Outstanding	466,875
Cancelled / forfeited, Options Outstanding	0
Exercised, Options Outstanding	(2,600)
Options Outstanding, Ending balance	842,255
Vested and Exercisable, Options Outstanding	375,380
Weighted-Average Exercise Price, Options Beginning balance	$ 41.81
Options granted, Weighted-Average Exercise Price	7.61
Options cancelled / forfeited, Weighted-Average Exercise Price	0
Options exercised, Weighted-Average Exercise Price	5.32
Weighted-Average Exercise Price, Options Ending balance	22.96
Vested and Exercisable, Weighted-Average Exercise Price	$ 42.06
Aggregate Intrinsic Value, Options Beginning balance	$ 37,440
Options Exercised, Aggregate Intrinsic Value	8,580
Aggregate Intrinsic Value, Options Ending balance	168,742
Vested and Exercisable, Aggregate Intrinsic Value	$ 26,936

Stockholders' Equity - Fair Value of Employee Stock Purchase Plan (Parenthetical) (Detail)	Sep. 30, 2020 Participant
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Participants enrolled in the employee stock purchase plan	0
2016 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Participants enrolled in the employee stock purchase plan	0

Stockholders' Equity - Stock-based Compensation Expense and Valuation Information - Additional Information (Detail)	6 Months Ended
	Sep. 30, 2020 USD ($) Participant
Class Of Stock [Line Items]
Total unrecognized compensation cost related to unvested stock option grants	$ 2,866,000
Participants enrolled in the employee stock purchase plan \| Participant	0
Stock options [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	3 years 7 months 2 days
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	2 years 1 month 20 days
Unrecognized stock-based compensation expense	$ 35,000
Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Total unrecognized compensation cost related, weighted average period	9 months
Unrecognized stock-based compensation expense	$ 45,000

Description of Business - Additional Information (Detail)	6 Months Ended
	Sep. 30, 2020 USD ($) Vote
Messrs. Murphy [Member]
Description Of Business [Line Items]
Number of votes secured	59,229,909
Percentage of vote received in re-election of annual meeting	98.90%
Stern [Member]
Description Of Business [Line Items]
Number of votes secured	59,147,657
Percentage of vote received in re-election of annual meeting	98.80%
Advisory Nominees [Member]
Description Of Business [Line Items]
Number of votes secured	54,368,360
Percentage of vote received in re-election of annual meeting	91.40%
Maximum [Member]
Description Of Business [Line Items]
Reimbursement of merger-related expenses \| $	$ 300,000

Stockholders' Equity - Summary of Company's Restricted Stock Units Activity and Performance-Based Restricted Stock Units Activity (Detail)	6 Months Ended
	Sep. 30, 2020 $ / shares shares
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares \| shares	18,116
Granted, Number of Shares \| shares	0
Vested, Number of Shares \| shares	(16,377)
Canceled / forfeited, Number of Shares \| shares	0
Ending balance, Unvested, Number of Shares \| shares	1,739
Beginning balance, Unvested, Weighted Average Price \| $ / shares	$ 43.49
Granted, Weighted Average Price \| $ / shares	0
Vested, Weighted Average Price \| $ / shares	45.83
Canceled / forfeited, Weighted Average Price \| $ / shares	0
Ending balance, Unvested, Weighted Average Price \| $ / shares	$ 21.46
Performance-Based Restricted Stock Units [Member]
Class Of Stock [Line Items]
Beginning balance, Unvested, Number of Shares \| shares	197,644
Granted, Number of Shares \| shares	0
Vested, Number of Shares \| shares	(185,415)
Canceled / forfeited, Number of Shares \| shares	0
Ending balance, Unvested, Number of Shares \| shares	12,229
Beginning balance, Unvested, Weighted Average Price \| $ / shares	$ 10.24
Granted, Weighted Average Price \| $ / shares	0
Vested, Weighted Average Price \| $ / shares	10.27
Canceled / forfeited, Weighted Average Price \| $ / shares	0
Ending balance, Unvested, Weighted Average Price \| $ / shares	$ 9.80

Related Parties - Additional Information (Detail)	6 Months Ended
Related Parties - Additional Information (Detail)	Sep. 30, 2020 USD ($) Employee	Mar. 31, 2020 USD ($)	Sep. 30, 2019 USD ($)
Related Party Transaction [Line Items]
Accounts receivable	$ 19,000	$ 111,000
Viscient Biosciences [Member]
Related Party Transaction [Line Items]
Accounts receivable	$ 19,000		$ 71,000
Number of employees hired \| Employee	3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Mar. 31, 2020
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	6,732,090	6,527,900
Common stock, shares outstanding	6,732,090	6,527,900

Stockholders' Equity - Treasury Stock - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Aug. 31, 2020	Sep. 30, 2020
Class Of Stock [Line Items]
Treasury stock purchased	46
Cost of shares of treasury stock purchased		$ 1,000
Maximum [Member]
Class Of Stock [Line Items]
Cost of shares of treasury stock purchased	$ 100,000

Stockholders' Equity - Preferred Stock - Additional Information (Detail)	Sep. 30, 2020 shares
Equity [Abstract]
Preferred stock, shares authorized	25,000,000
Preferred stock, shares outstanding	0

Restructuring - Additional Information (Details)	3 Months Ended					6 Months Ended		12 Months Ended
Restructuring - Additional Information (Details)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Mar. 31, 2020 USD ($) Employee
Restructuring Cost And Reserve [Line Items]
Number of employees terminated \| Employee								52
Percentage of workforce terminated								90.00%
Restructuring charges	$ 2,808,000				$ 2,456,000	$ 2,808,000	$ 2,456,000
Employee Severance and Benefits Costs [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring charges						$ 2,800,000		$ 2,700,000
Payments for restructuring	$ 2,600,000		$ 100,000	$ 900,000	$ 1,700,000
Quarterly restructuring payment, description						The Company expects to pay approximately $30,000 each quarter through the end of fiscal 2022 as part of the severance and benefit obligations.
Expected quarterly restructuring payment						$ 30,000
Employee Severance and Benefits Costs [Member] \| Maximum [Member]
Restructuring Cost And Reserve [Line Items]
Payments for restructuring		$ 100,000